Will increased R&D spending pay off for the Synairgen share

Shares in Synairgen flopped after trials for its Covid-19 treatment were put on hold. Investors will be looking at how the company plans to reverse its losses when it delivers its full-year results.

Related Keywords

Richard Marsden , University Of Southampton , Phillip Monk ,